Biomarkers of Renal Dysfunction in Neuroblastoma Survivors

Memorial Sloan Kettering Cancer Center (MSK)

Status: Completed

Conditions: Neuroblastoma Survivors

Treatments: Other: Urine sample

Study type: Observational

Funder types: Other

Identifiers

NCT03947346

19-160

Details and patient eligibility

About

The main purpose of this study is to learn more about biomarkers of kidney function in the blood and urine of neuroblastoma survivors. A biomarker is a biological molecule found in blood, urine, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition.

Enrollment: 28 patients

Sex: All

Ages: Under 20 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of neuroblastoma between 0-18 years of age
• < 21 years of age at time of study enrollment
• Two or more years from completion of systemic chemotherapy and/or radiation therapy

Exclusion criteria

• Patients treated with observation only
• Patients with multiple primary cancers

Trial design

28 participants in 1 patient group

survivors of neuroblastoma treated with nephrotoxic therapy

Description:

Upon enrollment, all subjects will receive a urine collection kit by mail. Participants will bring in a first-morning urine specimen on the day of their routinely scheduled long-term follow-up visit, and will then have an additional blood and urine sample drawn with their other clinical care labs upon arrival to MSK.

Treatment:

Other: Urine sample